Lentrica

Desloratadine, the active ingredient in Lentrica, is a second‑generation H1 antagonist presented as an oral tablet for oral use. It treats allergic rhinitis and chronic idiopathic urticaria by reducing histamine‑mediated symptoms in adults and children.

GNH USA supplies Lentrica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Desloratadine is a second‑generation antihistamine that reduces histamine‑mediated symptoms in allergic conditions.

Allergic rhinitis: relief of nasal congestion, sneezing, itching and watery discharge. Chronic idiopathic urticaria: reduction of hives and associated itching. Allergic conjunctivitis: alleviation of eye itching, redness and tearing.

Desloratadine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Dry mouth: transient sensation of oral dryness. - Fatigue or mild somnolence: occasional tiredness. - Nausea: occasional upset stomach. - Dizziness: brief light‑headed feeling.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips or throat requiring urgent care. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Anaphylaxis: rapid onset of systemic allergic response. - Cardiac arrhythmia: rare reports of irregular heartbeat. - Hepatotoxicity: very rare liver enzyme elevations.

Before using Lentrica, consider the following safety points.

Hepatic impairment: dose may need adjustment in patients with severe liver disease. Known hypersensitivity: avoid if the patient has demonstrated allergy to desloratadine or related antihistamines. Pregnancy: consult a healthcare professional; benefits should outweigh potential risks. Breastfeeding: discuss with a physician as drug may pass into milk. Sedation potential: exercise caution when driving or operating machinery until individual response is known. Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Desloratadine may interact with other medicines; monitor accordingly.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase desloratadine plasma levels. - Concurrent use with other H1 antihistamines: can enhance sedative effects.

Moderate Interactions (Monitor Closely): - Alcohol or CNS depressants: may increase drowsiness. - CYP3A4 substrates (e.g., erythromycin, ritonavir): monitor for altered efficacy. - Anticholinergic agents: may exacerbate dry mouth. - Herbal supplements such as St. John’s wort: could reduce drug exposure.